Product image of Insuman Implantable (Insulin Human) supplied by GNH India

Insuman Implantable

Active Ingredient:
Insulin Human
Origin:
EU

Insuman Implantable (Insulin Human)

Insulin Human, the active ingredient in Insuman Implantable, is an insulin presented as an implantable form for intraperitoneal use. It treats diabetes mellitus in patients who require continuous basal insulin therapy. Insuman Implantable is marketed in the European Union and complies with relevant regulatory standards.

GNH India supplies Insuman Implantable as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insuman Implantable provides long‑acting insulin therapy for diabetes mellitus, acting on the glucose regulation pathway.

  • Type 1 Diabetes Mellitus: delivers continuous basal insulin to maintain glycemic control.
  • Type 2 Diabetes Mellitus: used as adjunctive basal insulin when oral agents are insufficient.
  • Secondary Diabetes (e.g., post‑pancreatectomy): supplies necessary insulin replacement for patients lacking endogenous production.

How It Works

  • Insulin Human binds to insulin receptors on peripheral tissues, activating intracellular signaling cascades that increase glucose uptake and utilization, while simultaneously suppressing hepatic gluconeogenesis. This dual action lowers circulating blood glucose levels and supports metabolic homeostasis.

Side Effects

Insuman Implantable may cause a range of adverse reactions.

Common Side Effects

  • Hypoglycemia: low blood glucose episodes, especially if dosing is excessive.
  • Injection site reactions: redness, swelling, or discomfort at the implantation site.
  • Weight gain: increased adipose tissue due to improved glucose utilization.
  • Edema: peripheral fluid accumulation.
  • Nausea: mild gastrointestinal upset.
  • Lipodystrophy: abnormal fat distribution around the implant site.

Serious or Rare Side Effects

  • Severe hypoglycemia: can lead to seizures, loss of consciousness, or injury.
  • Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention.
  • Insulin antibodies: may alter insulin effectiveness and cause resistance.
  • Severe injection site infection: requires prompt antimicrobial therapy.
  • Hypersensitivity pneumonitis: rare respiratory reaction.
  • Cardiovascular events: rare but possible in susceptible individuals.

Precautions & Warnings

When using Insuman Implantable, several safety considerations are recommended.

  • Dose adjustment: titrate based on regular blood glucose monitoring and clinical response.
  • Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk.
  • Hepatic impairment: use with caution; liver dysfunction can affect glucose metabolism.
  • Pregnancy and lactation: evaluate risk‑benefit ratio; insulin is generally preferred but individual assessment is needed.
  • Hypoglycemia awareness: educate patients on recognizing and treating low blood glucose.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insuman Implantable can interact with several drug classes.

Major Interactions (Avoid)

  • Beta‑blockers: may mask hypoglycemia symptoms, delaying recognition.
  • Sulfonylureas or other oral hypoglycemics: additive effect increasing severe hypoglycemia risk.
  • MAO inhibitors: potential synergistic glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may raise blood glucose, requiring dose adjustment.
  • Corticosteroids: can increase glucose levels, possibly necessitating higher insulin doses.
  • ACE inhibitors: may enhance insulin sensitivity, modestly affecting glucose control.

Frequently Asked Questions

Insuman Implantable is an implantable insulin formulation indicated for the long‑term management of diabetes mellitus. It provides continuous basal insulin delivery to help maintain stable blood glucose levels in patients with type 1, type 2, or secondary diabetes who require sustained insulin support.

Insulin Human mimics the body’s natural insulin by binding to insulin receptors on muscle, fat, and liver cells. This binding triggers cellular pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose production, thereby lowering circulating blood glucose concentrations.

The dose of Insuman Implantable is individualized and determined by the prescribing healthcare professional. Dosing is based on factors such as the patient’s blood glucose targets, body weight, renal and hepatic function, and overall clinical response.

Insulin is generally considered the treatment of choice for diabetes during pregnancy because it does not cross the placenta in significant amounts. However, specific safety data for the implantable form are limited, so clinicians should weigh potential benefits against any unknown risks and monitor both mother and fetus closely.

To order Insuman Implantable, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Unlike conventional injectable insulins that require frequent dosing, Insuman Implantable delivers a steady basal insulin supply from a single intraperitoneal implant. This can reduce injection frequency and improve adherence, but it requires a minor surgical procedure for placement and careful monitoring for implant‑related reactions.

Insuman Implantable should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold chain to preserve insulin potency.

The implant is placed intraperitoneally by a qualified healthcare professional, typically in a minor surgical setting. Once positioned, the device releases insulin continuously over an extended period, eliminating the need for daily injections.

The most critical risks include severe hypoglycemia, which can lead to seizures or loss of consciousness, and allergic or anaphylactic reactions at the implant site. Prompt recognition and treatment of these events are essential, and patients should be educated on warning signs.

Patients with a known hypersensitivity to insulin human or any component of the implant formulation should avoid its use. Additionally, individuals with uncontrolled infection at the implantation site, severe hepatic or renal failure, or those unable to undergo the implantation procedure should not be treated with this product.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT